Advanced glycation end products and the kidney

被引:301
|
作者
Bohlender, JM [1 ]
Franke, S [1 ]
Stein, G [1 ]
Wolf, G [1 ]
机构
[1] Univ Klin Jena, Innere Med Klin 3, Dept Internal Med 3, Jena, Germany
关键词
RAGE; diabetic nephropathy; progression of renal disease; inflammation; glycoxidation;
D O I
10.1152/ajprenal.00398.2004
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Advanced glycation end products (AGEs) are a heterogeneous group of protein and lipids to which sugar residues are covalently bound. AGE formation is increased in situations with hyperglycemia ( e. g., diabetes mellitus) and is also stimulated by oxidative stress, for example in uremia. It appears that activation of the renin-angiotensin system may contribute to AGE formation through various mechanisms. Although AGEs could nonspecifically bind to basement membranes and modify their properties, they also induce specific cellular responses including the release of profibrogenic and proinflammatory cytokines by interacting with the receptor for AGE ( RAGE). However, additional receptors could bind AGEs, adding to the complexity of this system. The kidney is both: culprit and target of AGEs. A decrease in renal function increases circulating AGE concentrations by reduced clearance as well as increased formation. On the other hand, AGEs are involved in the structural changes of progressive nephropathies such as glomerulosclerosis, interstitial fibrosis, and tubular atrophy. These effects are most prominent in diabetic nephropathy, but they also contribute to renal pathophysiology in other nondiabetic renal diseases. Interference with AGE formation has therapeutic potential for preventing the progression of chronic renal diseases, as shown from data of animal experiments and, more recently, the first clinical trials.
引用
收藏
页码:F645 / F659
页数:15
相关论文
共 50 条
  • [21] The impact of advanced glycation end products on bone properties in chronic kidney disease
    Damrath, John G.
    Creecy, Amy
    Wallace, Joseph M.
    Moe, Sharon M.
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2021, 30 (04): : 411 - 417
  • [22] Association of advanced glycation end products with sarcopenia and frailty in chronic kidney disease
    Yabuuchi, Junko
    Ueda, Seiji
    Yamagishi, Sho-ichi
    Nohara, Nao
    Nagasawa, Hajime
    Wakabayashi, Keiichi
    Matsui, Takanori
    Yuichiro, Higashimoto
    Kadoguchi, Tomoyasu
    Otsuka, Tomoyuki
    Gohda, Tomohito
    Suzuki, Yusuke
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [23] Advanced Glycation End Products:Receptors for Advanced Glycation End Products Axis in Coronary Stent Restenosis: A Prospective Study
    Pearce, Colin
    Islam, Naorin
    Bryce, Robyn
    McNair, Erick Donnell
    INTERNATIONAL JOURNAL OF ANGIOLOGY, 2018, 27 (04) : 213 - 222
  • [24] Immunohistochemical demonstration of advanced glycation end products and the effects of advanced glycation end products in ossified ligament tissues in vitro
    Yokosuka, Kimiaki
    Park, Jin Soo
    Jimbo, Kotaro
    Yoshida, Tatuhiro
    Yamada, Kei
    Sato, Kimiaki
    Takeuchi, Masayoshi
    Yamagishi, Sho-ichi
    Nagata, Kensei
    SPINE, 2007, 32 (11) : E337 - E339
  • [25] Hemodialysis techniques and advanced glycation end products
    Tessitore, N
    Lapolla, A
    Aricó, CN
    Gammaro, L
    Bernich, P
    Fedele, D
    ADVANCED GLYCATION END PRODUCTS IN NEPHROLOGY, 2001, 131 : 33 - 39
  • [26] Advanced glycation end products and insulin resistance
    Unoki, Hiroyuki
    Yamagishi, Sho-ichi
    CURRENT PHARMACEUTICAL DESIGN, 2008, 14 (10) : 987 - 989
  • [27] Advanced glycation end-products: a review
    Singh, R
    Barden, A
    Mori, T
    Beilin, L
    DIABETOLOGIA, 2001, 44 (02) : 129 - 146
  • [28] Advanced glycation end products in AA amyloidosis
    Röcken, C
    Schwan, M
    Mansfeld, S
    Raynes, J
    Stix, B
    Saeger, W
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2001, 8 : 46 - 47
  • [29] Advanced Glycation End Products in Health and Disease
    Reddy, V. Prakash
    Aryal, Puspa
    Darkwah, Emmanuel K.
    MICROORGANISMS, 2022, 10 (09)
  • [30] Advanced glycation end products: Detection and reversal
    Al-Abed, Y
    Kapurniotu, A
    Bucala, R
    AMYLOID, PRIONS, AND OTHER PROTEIN AGGREGATES, 1999, 309 : 152 - 172